REFERENCES
- Panagiotis Tsikouras, Stefanos Zervoudis, Bachar Manav et al. Cervical
cancer: screening, diagnosis and staging. JBUON. 2016;1(2): 320-325
- Patrizia Vic, Luciano Mariani, Laura Pizzuti, et al. Immunologic
treatments for precancerous lesions and uterine cervical cancer.
Journal of Experimental and Clinical Cancer Research. 2014;33:29
- Zheng Hu, Ding MA. The precision prevention and therapy of HPV-related
cervical cancer: new concepts and clinical implications. Cancer Med.
2018;7(10):5217-5236
- Panagiotis Tsikouras, Stefanos Zeroudis, Bachar Manav, et al. Cervical
cancer: screening, diagnosis and staging. Journal of B. U. ON.
2016;21(2):320-5
- Sebastian Wardak. Human Papillomavirus(HPV) and cervical cancer. Med
Dosw Mikrobiol. 2016;68(1):73-84
- Gregoire Marret, Edith Borcoman, Christophe Le Tourneau. Pembrolizumab
for the treatment of cervical cancer. Expert Opin Biol Ther.
2019;19(9):871-877
- Sudeep Gupta, Amita Maheshwari, Pallavi Parab, et al. Neoadjuvant
Chemotherapy Followed by Radical Surgery Versus Concomitant
Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB
Squamous Cervical Cancer: A Randomized Controlled Trial. Journal of
Clinical Oncology. 2018; 36(16):1548-1555
- Lise M A De Strooper,Johannes Berkhof,Renske D M Steenbergen, et
al. Cervical cancer risk in HPV-positive women after a negative
FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM
trial with 14 year follow-up. International Journal of Cancer.
2018;143(6):1541-1548
- Gulden Menderes, Jonathan Black, Carlton L Schwab et al. Immunotherapy
and targeted therapy for cervical cancer: an update. Expert Review of
Anticancer Therapy. 2016;16(1):83-98
- Elisena Franzese, Sara Centonze, Anna Diana, et al. PARP inhibitors in
ovarian cancer. Cancer Treatment Reviews. 2019;73:1-9
- Diagnosis and Treatment Recommendation and Exploration for Critical
and Refractory Adverse Effects Related to Immunocheckpoint Inhibitors.
Chinese Journal of Lung Cancer. 2019;22(10):605-614
- Lauren M Cuevas, Adil I Daud. Immunotherapy for melanoma. Semin Cutan
Med Surg. 2018;37(2):127-131
- Suzanne L., F. Stephen Hodi, Julie R., et al. Safety, activity, and
immune correlates of anti-PD-1 antibody in cancer. The New England
Journal of Medicine. 2012;366(26):2443-54
- Elizabeth K Lee, Panagiotis A Konstantinopoulos. Combined PARP and
immune checkpoint inhibition in ovarian cancer. Trends Cancer.
2019;5(9):524-528
- Leonie Voorwerk, Maarten Slagter, Hugo M Horlings et al. Immune
induction strategies in metastatic triple-negative breast cancer to
enhance the sensitivity to PD-1 blockade: the TONIC trial. Nature
Medicine. 2019;25(6):920-928
- Haoran Li, Xiaohua Wu, and Xi Cheng. Advances in diagnosis and
treatment of metastatic cervical cancer. J Gynecol Oncol.
2016;27(4):e43
- Arlene H Sharpe, Kristen E Pauken. The diverse functions of the PD1
inhibitory pathway. Nature Reviews Immunology. 2018;18(3):153-167
- L Paré , T Pascual , E
Seguí , et al. Association between PD1 mRNA and
response to anti-PD1 monotherapy across multiple cancer types. Annals
of Oncology. 2018;29(10):2121-2128
- Jacob P. Smeltzer, Jason M. Jones, Steven C. Ziesmer, et al. Pattern
of CD14+ follicular dendritic cells and PD1+ T cells independently
predicts time to transformation in follicular Lymphoma. Clin Cancer
Res. 2014;20(11):2862-2872
- Heng Lin, Shuang Wei, Elaine M., Host expression of PD-L1 determines
efficacy of PD-L1 pathway blockade-mediated tumor regression. The
Journal of Clinical Investigation. 2018;128:805-815
- Zhifang C.,Nannan P.,Rong D.,et al. Elevated Expression of Programmed
Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune
Response against Cervical Cancer Cell. Mediators of Inflammation.
2016;2016:6891482
- Loise M. Francisco, Peter T. Sage, Arlene H. Sharp. The PD-1 pathway
in tolerance and autoimmunity. Immunological Reviews. 2010; 236:219-42
- Schoonderwoerd Mark J A, Koops Maaike F M, Angela Ricardo A, et al.
Targeting Endoglin-Expressing Regulatory T Cells in the Tumor
Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor
Immunotherapy. Clinical cancer research : an official journal of the
American Association for Cancer Research. 2020;26(14):3831-3842
- Dickson Adah, Yijun Yang, Quan Liu, et al. Plasmodium infection
inhibits the expansion and activation of MDSCs and Tregs in the tumor
microenvironment in a murine Lewis lung cancer model. Cell Commun
Signal. 2019;17:32
- Haiping Wang, Fabien Franco, Ping-Chih Ho. Metabolic regulation of
Tregs in cancer: opportunities for immunotherapy. Trends Cancer.
2017;3(8):583-592
- Patrick R Adair, Yong Chan Kim, Ai-Hong Zhang, et al. Human Tregs made
antigen specific by gene modification: the power to treat autoimmunity
and antidrug antibodies with precision. Front Immunology. 2017;8:1117
- Shimon Sakaguchi, Tomoyuki Yamaguchi, Takashi Nomura, et al.
Regulatory T cells and immune tolerance. Cell. 2008;133(5):775-87
- Ye Shu, Qinghua Hu, Hai Long, et al. Epigenetic variability of
CD4+CD25+Tregs contributes to the pathogenesis of autoimmune diseases.
Clinical Reviews in Allergy & immunology. 2017;52(2):260-272
- Antonio La Cava. Natural Tregs and autoimmunity. Front
Biosci.2009;14:333-43
- Mehmet Altan, Kelley M. Kidwell, Vasiliki Pelekanou, et al.
Association of B7H4, PD-L1, and tumor infiltrating lymphocytes with
outcomes in breast cancer. NPJ Breast Cancer. 2018;4:40
- Schalper, K. A. et al. In situ tumor PD-L1 mRNA expression is
associated with increased TILs and better outcome in breast
carcinomas. Clin. Cancer Res. 2014;20:2773-2782
- Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other
features of the tumor immune microenvironment with response to
anti-PD-1 therapy. Clin. Cancer Res. 2014;20:5064-5074
- Velcheti, V. et al. Programmed death ligand-1 expression in non-small
cell lung cancer. Lab. Investing. 2014;94:107-116